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Abstract 25 
Background: Central augmentation index (cAIx) is an indicator for vascular stiffness. 26 
Obstructive and aneurysmatic vascular disease can affect pulse wave propagation and 27 
reflection, causing changes in central aortic pressures. 28 
Aim: To assess and compare cAIx in patients with peripheral arterial disease (PAD) and / or 29 
abdominal aortic aneurysm (AAA).  30 
Methods: cAIx was assessed by radial applanation tonometry (Sphygmocor) in a total of 184 31 
patients at a tertiary referral centre. Patients were grouped as having PAD only, AAA only, or 32 
both AAA and PAD. Differences in cAIx measurements between the three patient groups 33 
were tested by non-parametric tests and stepwise multivariate linear regression analysis to 34 
investigate associations with obstructive or aneurysmatic patterns of vascular disease. 35 
Results: In the study sample of 184 patients, 130 had PAD only, 20 had AAA only, and 34 36 
patients had both AAA and PAD. Mean cAIx (%) was 30.5 ± 8.2 across all patients. It was 37 
significantly higher in females (35.2 ± 6.1, n=55) than males (28.4 ± 8.2, n=129), and 38 
significantly higher in patients over 80 years of age (34.4 ± 6.9, n=22) than in those under 80 39 
years (30.0 ± 8.2, n=162). Intergroup comparison revealed a significant difference in cAIx 40 
between the three patient groups (AAA: 27.3 ± 9.5; PAD: 31.4 ± 7.8; AAA & PAD: 28.8 ± 41 
8.5). cAIx was significantly lower in patients with AAA, higher in patients with both AAA 42 
and PAD, and highest in patients with PAD only (beta = 0.21, p = 0.006). 43 
Conclusion: Non-invasive assessment of arterial stiffness in high-risk patients indicates that 44 
cAIx differs according to the pattern of vascular disease. Measurements revealed significantly 45 
higher cAIx values for patients with obstructive peripheral arterial disease than for patients 46 
with aneurysmatic disease. 47 
 48 
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Introduction 49 
Atherosclerotic disease is the leading cause of mortality and morbidity in the Western world. 50 
The term encompasses coronary artery disease, cerebrovascular disease, peripheral arterial 51 
disease and aortic aneurysm [1]. Peripheral arterial disease (PAD) leads to a 2-5 fold increase 52 
in cardiovascular mortality [2-3]. Likewise, patients suffering from an aneurysm of the 53 
abdominal aorta (AAA) have an elevated risk of cardiovascular morbidity and mortality, due 54 
to the risk factors and comorbidities associated with aneurysm, and the risk of aneurysm 55 
rupture which has a very high mortality rate [4-7]. In this study, we use the term PAD to refer 56 
to patients with stenotic or occlusive arterial disease of the lower extremities only. PAD is 57 
often associated with AAA [8].  58 
The treatment of cardiovascular risk factors, such as arterial hypertension, is important in 59 
reducing morbidity and mortality in both PAD and AAA patients. Current guidelines for anti-60 
hypertensive treatment are based on peripheral blood pressure measurements. However, in 61 
recent years central hemodynamic parameters have been ascribed an increasingly important 62 
role in the evaluation of cardiovascular risk. In particular, both increased central blood 63 
pressure and increased arterial stiffness have been shown to be independently associated with 64 
a poor cardiovascular outcome [9-12].  65 
Arterial stiffness is a feature of both obstructive and aneurysmatic vascular diseases [13-14], 66 
and results from a loss of elasticity in the arterial wall. Currently, carotid-femoral pulse wave 67 
velocity (PWV) measurement is regarded as the gold standard method for assessment of 68 
arterial stiffness [15-16]. Other, indirect, measures of aortic stiffness include the central 69 
augmentation index (cAIx) [15]. In addition to pulse wave velocity, cAIx provides 70 
information on wave reflection patterns.  71 
The pulse wave in any vascular segment is composed of a forward and backward wave, and 72 
its shape is dependent on the timing and magnitude of those two waves. The impact of the 73 
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reflected wave is related to its early superimposition onto the forward wave and the 74 
magnitude and distribution of the reflected waves. Pressure waveforms can be recorded non-75 
invasively by applanation tonometry. Different parameters have been defined in pulse wave 76 
analysis [16-18]. The central aortic augmentation index (cAIx) is defined as the pressure 77 
difference between the first and second systolic peaks (P2-P1=Augmentation Pressure) 78 
expressed as a percentage of the pulse pressure (PP), which is the difference between diastolic 79 
and systolic blood pressure. The parameter provides an indication of the influence of reflected 80 
waves on the total pulse pressure. Apart from a high pulse wave velocity, changes in 81 
reflection sites can also influence the augmentation index. Both obstructive and aneurysmatic 82 
vascular disease patterns affect pulse wave propagation, due to changes in arterial wall 83 
characteristics.  84 
To date, there has been no analysis directly comparing arterial stiffness parameters in these 85 
two disease patterns. We aimed to explore differences in arterial stiffness between obstructive 86 
and aneurysmatic disease patterns (patients with PAD, AAA or both) through non-invasive 87 
assessment of central hemodynamic markers. We used the cAIx recorded at the radial artery 88 
as our primary measure for arterial stiffness rather than carotid-femoral PWV, because aortic 89 
aneurysm and/or obstruction of the iliac arteries located in the direct axis for measurement of 90 
PWV would have influenced results. 91 
 92 
Methods 93 
Patient selection and study design 94 
This was an open, non-randomized, comparative study conducted at a tertiary referral centre. 95 
The local ethics committee (Kantonale Ethikkommission Zürich, Stampfenbachstrasse 121, 96 
8090 Zürich, Switzerland) approved the study (Nr. 1741/2009) and all patients gave written 97 
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informed consent. The study was conducted according to Good Clinical Practice standards. 98 
Data was collected and analysed from a total of 184 patients. Patients were divided into three 99 
groups: a) PAD only, b) AAA only, and c) patients with both AAA and PAD. 100 
For all patients the following data was collected: medical history, brachial systolic and 101 
diastolic blood pressures, body mass index, vascular risk factors, comorbidities, medication, 102 
and radial artery pulse wave analysis as described below.  103 
Patients were defined as having PAD if the ankle-brachial index (ABI) measurement was 104 
<0.9, or if ABI was >0.9 concomitant with a history of lower limb revascularization; patients 105 
had chronic and stable PAD that had been graded into Rutherford I-III according to their 106 
medical history. Measurements of cAIx in PAD patients were taken before any planned 107 
vascular intervention. Patients were defined as having AAA if an aneurysm of the abdominal 108 
aorta was present with a diameter of 3cm or greater, as described below. 109 
All patients with AAA were evaluated for PAD based on information in their medical history 110 
and ankle-brachial pressure measurements. All PAD patients were screened for concomitant 111 
AAA using information acquired from their medical records, including existing ultrasound, 112 
CT and MRI images. The difference between the date of our cAIx measurements and the date 113 
of ultrasound, CT and MRI measurements was 24 months on average.  114 
To verify our measurements for pulse wave analysis we performed measurements in a group 115 
of 18 healthy unmatched controls with no known cardiovascular risk factors (mean age 35 ± 116 
10.7 years; female 66%, male 33%). For characteristics of this unmatched control group see 117 
S2 Table in the Supporting Information.  118 
 119 
Ankle-brachial arterial pressure index assessment 120 
Ankle-brachial arterial pressure index (ABI) assessments were performed as part of the 121 
standard diagnostic procedure. Standard brachial systolic and diastolic blood pressures on 122 
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both arms were measured in triplicate using a traditional cuff manometer, according to Riva 123 
Rocci methods. Systolic ankle blood pressures, of the posterior tibial artery and anterior tibial 124 
artery, on both legs, were obtained by hand-held 6 MHz Doppler probe (Kranzbühler, 125 
Logidop 2, Pilger Medical Electronics, Switzerland). For each leg, ABI was calculated as the 126 
ratio of the highest ankle systolic blood pressure to the highest brachial systolic blood 127 
pressure; the lower of these two ABI values was taken as the study parameter. 128 
 129 
Abdominal aortic aneurysm diameter measurements 130 
The maximum abdominal aortic diameter was measured using ultrasound, CT or MRI 131 
angiography imaging techniques. The diameter of the abdominal aorta was defined as the 132 
maximum cross-sectional diameter (including the vessel wall), measured orthogonally to the 133 
estimated vessel centre line. Abdominal aortic aneurysm was defined as a diameter of 3cm or 134 
greater in the abdominal section of the infra-diaphragmatic aorta. 135 
 136 
Pulse wave analysis 137 
Pulse wave analysis was conducted with applanation tonometry. All measurements were 138 
performed with the patient in the supine position. To record the central pressure waveform the 139 
indirect method of arterial tonometry was used: pressure waveform was recorded at the radial 140 
artery, and using the generalized transfer function it was converted into a calculated central 141 
pressure waveform [19]. All measurements were performed with the SphygmoCor device and 142 
designated software (AtCor Medical Pty. Ltd., Sydney, Australia). SphygmoCor uses a high 143 
fidelity Millar strain-gauge transducer (Millar Instruments, Houston, TX) allowing for 144 
measurement of the first systolic peak (P1), the second systolic peak (P2), and the central 145 
pulse pressure (PP) from the calculated aortic waveform. AIx was then calculated as: 146 
 (1) 147 
 
AIx %( )= P2 − P1( )PP ∗100
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Because the heart rate is known to significantly affect AIx values, normalization was 148 
performed to a standard heart rate of 75bpm (Aix@75): 149 
. [20] 150 
 151 
Statistical analysis 152 
Statistical analyses were carried out using Stata/SE11.2 for Windows. Patient characteristics 153 
were presented as mean ± standard deviation or as absolute frequency and percent. The non-154 
parametric Kruskal-Wallis test was used for comparison of mean cAIx between patient 155 
groups: first, differences in mean cAIx were analysed for age, gender, BMI and height; 156 
second, differences in mean cAIx were analysed by diagnosis (AAA only, PAD and AAA, 157 
and PAD only), also taking age and gender into account.  158 
Multivariate regression analysis was applied, directly controlling for heterogeneities between 159 
patients. The dependent variable was cAIx@75. In a first model, cAIx in our patient groups 160 
was compared to cAIx in a control group of healthy individuals. Subsequently, cAIx was 161 
compared between patients grouped by diagnosis: the main explanatory variable, diagnosis, 162 
was defined as an ordinal variable taking the value 1 if a patient suffered from AAA, the 163 
value 2 if a patient suffered from AAA and PAD, and the value 3 if a patient suffered from 164 
PAD. In addition to the diagnosis the following control variables were included in four 165 
stepwise regressions: (i) age, gender, weight, height; then (i) and (ii) hypertension, smoking 166 
and diabetes; then (i) and (iii) coronary heart disease and cerebrovascular disease; and finally 167 
(i) and (iv) medication. It was not possible to control for medication and risk factors in the 168 
same specification as this introduced multi-collinearity. In order to check the robustness of 169 
our results, multivariate regression was repeated – first, by only including significant 170 
variables from the above four stepwise regressions, and second, by defining diagnosis as three 171 
binary variables.  172 
 
AIx@75 = AIx − 0.39∗ 75 − HR( )
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 173 
Results 174 
Patient characteristics  175 
The study sample consisted of 184 patients: 71% (n= 130) had PAD only, 18% (n=34) 176 
suffered from PAD and AAA and 11% (n=20) had aortic aneurysm only.  177 
Table 1 shows the patient characteristics for the three study groups. There was considerable 178 
heterogeneity within the respective groups of patients, particularly with regard to age and 179 
gender. In addition, the patients were shown to have cardiovascular comorbidities and 180 
cardiovascular risk factors known to be typical of patients with PAD and aneurysm. 181 
 182 
Table 1. Patient Characteristics 183 
 AAA PAD AAA and PAD 
 (n=20) (n=130) (n=34) 
Age, years 64.25 ± 8.08 68.70 ± 10.74 68.21 ± 5.77 
Male, n (%)  18 (90) 82 (63) 29 (85) 
Weight, kg 83.10 ± 11.65 72.63 ± 13.86 76.58 ± 11.57 
Height, m 1.74 ± 0.09 1.68 ± 0.08 1.72 ± 0.08 
BMI, kg/m2 27.60 ± 3.57 25.53 ± 4.08 25.89 ± 3.37 
Waist, cm 101.75 ± 10.35 97.37 ± 12.52 101.75 ± 12.51 
Hip, cm 104.90 ± 7.85 102.00 ± 8.11 103.69 ± 12.10 
Waist-hip ratio  0.97 ± 0.07 0.95 ± 0.08 0.98 ± 0.08 
Cardiovascular Comorbidities    
Coronary artery disease, n (%) 12 (60) 35 (27) 17 (50) 
Cerebrovascular disease, n (%) 0 (0) 35 (27) 8 (24) 
Renal insufficiency, n (%) na 26 (20) 1 (9) 
Cardiovascular risk factors    
Dyslipidemia, n (%) 14 (70) 81 (62) 30 (88) 
Diabetes, n (%) 3 (15) 36 (28) 5 (15) 
Current Smoking, n (%) 6 (30) 98 (75) 20 (59) 
Arterial hypertension, n (%) 15 (75) 106 (82) 32 (94) 
Medication    
Lipid lowering, n (%) 14 (70) 110 (85) 30 (88) 
ACE inhibitor, n (%)  7 (35) 48 (37) 15 (44) 
AT-II receptor blocker, n (%) 6 (30) 33 (25) 11 (32) 
Aldosterone receptor antagonist, n (%) 0 5 (4) 3 (9) 
β-blocker, n (%) 13 (65) 53 (41) 26 (76) 
α1-adreno-receptor blocker, n (%) 2 (10) 1 (1) 1 (3) 
Calcium channel blocker, n (%) 6 (30) 39 (30) 8(24) 
Diuretics, n (%) 8 (40) 54 (42) 17 (50) 
Nitrates, n (%) 1 (5) 4 (3) 1 (3) 
Notes: n denotes the number of observations 184 
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 185 
Figure 1 illustrates the diagnoses by gender and age. The median age of female patients with 186 
aneurysm was 60 years, while the median age of male patients with aneurysm was 68 years. 187 
For PAD, the median age of female patients was 75 years, while the median age of male 188 
patients was 65 years. Regarding the minimum and maximum ages, there were outliers for 189 
female patients with PAD and for male patients with aneurysm. 190 
 191 
Fig 1. Distribution of Age by Gender and Diagnoses 192 
 193 
Analysis of cAIx according to diagnosis, age and gender 194 
Table 2 presents cAIx values according to patient characteristics. The cAIx was significantly 195 
higher in female patients (p = 0.00). The cAIx increased with age, with a significant 196 
difference between the three age groups (p = 0.01). It was not correlated with BMI (p = 0.93), 197 
but was significantly lower for taller patients (p= 0.00). 198 
 199 
Table 2. Comparison of cAIx by Patient Characteristics  200 
  AIx (%) N p-value 
Gender Female 35.24 ± 6.05 55 0.00 
Male 28.44 ± 8.18 129  
Age (years) <65 28.01 ± 8.23 60 0.01 
65-79 31.10 ± 8.03 102  
>80 34.32 ± 7.19 22  
BMI <25 30.60 ± 8.17 83 0.93 
25-30 30.50 ± 8.09 68  
>30 30.10 ± 8.77 33  
Height (cm) <160 36.75 ± 6.07 19 0.00 
160-175 30.43 ± 7.54 120  
>175 28.00 ± 9.36 45  
Notes: The table shows the sample means of the cAIx@75 (heart rate 75 bpm). The p-values refer to the 201 
Kruskal-Wallis test without ties, used to determine whether cAIx was significanlty different for gender, age, 202 
BMI and height.  203 
 204 
 205 
 206 
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Table 3 illustrates cAIx results according to patient groups and diagnosis. There was a  207 
difference in cAIx between diagnoses: patients suffering from PAD-only had higher average 208 
cAIx values than the other groups, however this was significant at the 10% level only (p = 209 
0.06). We did not see significant differences in cAIx between the three patient groups when 210 
split up by age and gender. However, patient groups by age and gender were not “matched” 211 
well due to the low number of observations, which may have affected results and also made it 212 
impossible to conduct significance tests for all age-gender categories (n/a values). 213 
 214 
Table 3. Comparison of cAIx by Diagnosis, Gender and Age. 215 
  Aneurysm PAD Aneurysm and PAD Kruskall-Wallis 
test 
  mean cAIx @heart 
rate 75 (%) 
mean cAIx @heart 
rate 75(%) 
mean cAIx @heart 
rate 75 (%) 
p-value 
All  27.28 ± 9.47 31.40 ± 7.80 28.84 ± 8.46 0.06 
Female  <65 31.71 ± 6.16 34.13 ± 7.60 n/a 1.00 
65-79 40.42 ± 6.16 36.00 ± 4.97 33.34 ± 6.47 0.37 
>80 n/a 35.43 ± 6.63 n/a n/a 
Male <65 23.90 ± 9.70 28.24 ± 8.00 22.92 ± 5.83 0.18 
65-79 27.23 ± 9.48 29.37 ± 7.60 30.02 ± 8.79 0.59 
>80 n/a 32.11 ± 7.58 n/a n/a 
Notes: The table shows the sample means of cAIx@75 (heart rate 75 bpm). The p-values refer to the Kruskal-216 
Wallis test without ties, which was used to determine whether cAIx differed significantly between diagnoses.  217 
 218 
 219 
Analysis of cAIx according to diagnosis and comorbidities 220 
Table 4 summarises cAIx in our study population in regard to vascular comorbidities, with 221 
patients grouped according to the number of vascular territories affected by atherosclerosis: 222 
PAD and/or AAA, coronary artery disease (CAD), and cerebrovascular disease (CVD). The 223 
groupings were similar to those of the REACH Registry [21], but AAA was included in the 224 
PAD vascular territory. 95 patients (52%) had no known vascular comorbidity, 71 (38%) had 225 
either concomitant CAD or CVD, and 18 patients (10%) had all vascular beds affected. 226 
Differences in cAIx between these 3 groups were not found to be significant. 227 
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 229 
Table 4. Comparison of cAIx by Comorbidities 230 
 cAIx@heart rate 75 (%) Number of patients  (1): PAD and/or AAA 30.67 ± 8.86 95  (2): PAD and/or AAA and CAD or CVD 30.99 ± 7.64 71 (3): PAD and/or AAA and CAD and CVD 27.43 ± 6.28 18   231 
 232 
Multivariate analyses to explore factors influencing cAIx 233 
Our initial regression analysed differences between patients and a control group of healthy 234 
individuals, testing whether cAIx in the AAA, PAD and concurrent AAA & PAD patient 235 
groups was significantly different from cAIx in an unmatched control group of healthy 236 
individuals (Table 5). cAIx in all three patient groups was significantly different from the 237 
control group (p < 0.05 in all cases), with age, gender and heart rate taken into account. Age 238 
and gender had significant effects on cAIx. We adjusted cAIx for heart rate 75 using the 239 
above mentioned transfer function [20], therefore heart rate was not significant and was 240 
omitted from subsequent analyses. 241 
 242 
Table 5. Differences in cAIx between patients and a control group of healthy individuals 243 
R2=0.93, N=202 
Patient group or 
parameter 
Coefficient SE Beta p-value 
AAA 10.48 4.24 0.30 0.014 
PAD 9.58 3.89 0.43 0.015 
PAD & AAA 9.27 4.14 0.33 0.026 
Age 0.43 0.56 0.56 0.000 
Sex -3.18 1.32 -0.14 0.017 
Heart rate -0.52 0.37 -0.54 0.158 
Notes: The table shows results from multivariate linear regression analysis. SE denotes the standard errors of 244 
regression coefficients. The dependent variable is cAIx@75 (heart rate 75 bpm) 245 
 246 
 247 
Table 6 presents results of stepwise multivariate analyses of differences in cAIx between 248 
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patient groups with differing diagnoses. Model 1 showed that when holding basic 249 
characteristics constant (age, gender, height and weight), the “diagnosis” - categorised as 1 250 
(AAA), 2 (AAA & PAD) or 3 (PAD) - significantly influenced cAIx. Model 2 added controls 251 
for cardiovascular risk factors to the ‘basic characteristics’, namely for hypertension, smoking 252 
habits and diabetes: the significant positive effect of the diagnosis remained robust. Model 3 253 
included the ‘basic characteristics’ and focused on comorbidities. Coronary heart disease had 254 
a significant negative effect on cAIx, and the positive effect of diagnosis remained significant, 255 
however at the 10% level only (p = 0.063). Cerebrovascular disease was positively correlated 256 
with cAIx, but not significantly. Model 4 complemented Model 3, as it was not possible to 257 
include comorbidities and medication in the same model. Model 4 showed a significant 258 
negative effect of calcium channel blockers on cAIx (a lower and therefore improved cAIx 259 
value), as well as a borderline significant negative effect of diuretics on cAIx, corroborating 260 
the significant positive effect of diagnosis. In summary, Models 1 to 4 demonstrated that 261 
patients with PAD only, or AAA plus PAD, had a significantly higher cAIx than patients with 262 
AAA, even after controlling for a rich set of confounding factors. 263 
Models 5 and 6 tested the robustness of these results. Model 5 included all variables which 264 
were significant in Models 1 to 4, and diagnosis remained significant. Model 6 used an 265 
alternative specification of diagnosis: rather than including one ordinal variable which ranged 266 
from 1 to 3, it included two binary variables. The first took the value one if the patient 267 
suffered from PAD only and was zero otherwise; the second variable took the value one if the 268 
patient suffered from PAD and AAA. Results were therefore expressed relative to patients 269 
with AAA only. The model showed that cAIx was significantly higher for patients suffering 270 
from PAD only (p-value: 0.034) compared to patients suffering from AAA only.  271 
In order to test robustness further, a z-score Index was calculated (see S3 z-score in the 272 
Supporting Information). 273 
 274 
12  
 275 
 276 
Table 6. Differences in cAIx between patient groups 277 
Parameters Coefficient SE Beta p-value 
Model 1: R2=0.99, N=181     
Diagnosis 0.09 0.34 0.21 0.006 
Age 0.11 0.00 0.35 0.000 
Male -0.18 0.06 -0.27 0.004 
Height -1.43 0.64 -0.23 0.026 
Model 2: R2=0.99, N=181     
Diagnosis 0.08 0.04 0.18 0.029 
Hypertension -0.07 0.07 -0.09 0.256 
Diabetes -0.11 0.06 -0.16 0.042 
Smoker 0.08 0.04 0.12 0.140 
further controls: age, sex, 
height, weight. 
    
Model 3: R2=0.99, N=181     
Diagnosis 0.07 0.04 0.15 0.063 
Coronary Heart Disease -0.12 0.05 -0.18 0.023 
Cerebrovascular Disease 0.06 0.06 0.08 0.323 
further controls: age, sex, 
height, weight. 
    
Model 4: R2=0.99, N=181     
Diagnosis 0.08 0.03 0.17 0.023 
Statins 0.02 0.06 0.02 0.753 
ACE / AT II 0.02 0.05 0.04 0.666 
β-Blockers -0.07 0.05 -0.12 0.139 
CA-Ant. -0.11 0.05 -0.17 0.032 
Diuretics -0.09 0.05 -0.14 0.103 
further controls: age, sex, 
height, weight. 
    
Model 5: R2=0.99, N=181     
Diagnosis 0.09 0.03 0.19 0.014 
Age 0.01 0.00 0.39 0.000 
Male -0.12 0.06 -0.17 0.064 
Height -1.95 0.62 -0.31 0.002 
Diabetes -0.10 0.05 -0.14 0.064 
Coronary Heart Disease -0.10 0.05 -0.16 0.043 
CA-Ant. -0.14 0.05 -0.21 0.004 
Model 6: R2=0.99, N=181     
PAD 0.16 0.07 0.24 0.034 
PAD & AAA 0.10 0.08 0.12 0.248 
Age 0.01 0.00 0.39 0.000 
Male -0.12 0.06 -0.18 0.056 
Height -1.95 0.63 -0.31 0.002 
Diabetes -0.10 0.05 -0.14 0.074 
Coronary Heart Disease -0.11 0.05 -0.17 0.034 
CA-Ant. -0.14 0.05 -0.21 0.005 
Notes: The table shows results from multivariate linear regression analyses. SE denotes the standard errors of 278 
regression coefficients. The dependent variable is cAIx@75 (heart rate 75 bpm) 279 
 280 
 281 
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Discussion 282 
To the best of our knowledge, this is the first study to compare cAIx in patients with PAD and 283 
AAA. We found that the presence of peripheral arterial disease and / or abdominal aortic 284 
aneurysm was associated with an elevated cAIx and was highest in patients with PAD only, 285 
followed by patients with PAD and concomitant AAA, and lowest in patients with AAA 286 
without evidence for PAD. Although this study was based on a fairly low number of 287 
observations (n=184), and the patient groups differed in regard to number, age and sex, the 288 
results were consistent across a comprehensive range of analyses that took account of 289 
confounding factors.  290 
Previous studies have focused either on patients with PAD or AAA only. Several groups have 291 
reported an association between cAIx and PAD. Khalegi and Kullo found that cAIx was 292 
higher in patients with asymptomatic PAD compared to age- and sex-matched controls [22]. 293 
Brewer et al. [23] observed that lower cAIx was associated with more physical exercise 294 
(longer walking distances) in patients with PAD. In a previous study, we similarly found a 295 
significant correlation between ankle-brachial index and aortic augmentation index in PAD 296 
patients, and significant correlation for these patients between ABI and subendocardial 297 
viability ratio (another non-invasive hemodynamic marker derived from pulse wave analysis) 298 
[24]. In addition, we found that lower limb revascularization was associated with a 10% 299 
lowering in cAIx after 3 months when compared to a PAD control group treated 300 
conservatively [25]. Taken together, the existing literature lends support to the conclusion of 301 
our current study, that cAIx is a marker for arterial stiffness and is abnormally elevated in 302 
PAD. 303 
Concerning AAA, previous research does not present a similarly clear-cut picture. Lee et al. 304 
[26] studied a sample of 51 patients and found a significantly lower PWV and higher cAIx in 305 
patients with AAA compared to controls, arguing that these were not reliable markers in 306 
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patients with AAA. However, using a study group of only 19 patients, Moloney et al. found 307 
that cAIx improved after both open and endovascular repair implying a better compliance and 308 
further indicating that arterial stiffness markers were positively influenced by surgery [27]. In 309 
light of evidence that the rupture rate for AAA increases with aneurysm growth rate, Ruegg et 310 
al. did not find that cAIx differed significantly between fast and slow progressors [28]. 311 
The cAIx has been shown to be influenced by many different factors, such as: heart rate [29], 312 
age [30], gender (regardless of height) [31-34], height [35], ethnicity [36], risk factors and 313 
comorbidities (hypercholesterolemia [37], diabetes [38], renal failure [39]), and even living 314 
habits such as time spent watching television [40]. Our data conformed with results from 315 
previous studies in many respects, for example, cAIx in our patient group was strongly 316 
dependent on age (the difference between the three age groups in our patient sample was 317 
significant), gender (higher among females) and subject height. Also in line with previous 318 
research, cAIx was not associated with BMI [35]. Wilkinson et al. [29] demonstrated a 319 
negative effect of heart rate on cAIx. In our study, heart rate also had a significant effect, but 320 
our preferred specification was cAIx@75 (heart rate 75 bpm) (Table 5).  321 
As expected, we found that cAIx was elevated in patients with PAD compared to unmatched 322 
controls, consistent with Catalano et al.’s study of PWV in PAD patients [41]. cAIx was also 323 
elevated in patients with AAA compared to our unmatched controls. This demonstrates that 324 
cAIx can be an indicator of both occlusive and aneurysmatic arterial disease. 325 
Our novel contribution to the literature is in analyzing the relative elevation of cAIx in patient 326 
groups with different diagnoses. We showed that cAIx depended on the pattern, i.e. 327 
obstructive versus aneurysmal, of the disease. Given the confirmed sensitivity of cAIx with 328 
regard to patient characteristics, our preferred method of analysis was matching by age and 329 
gender. However we had very few observations in some of the groups, given our sample of 330 
184 patients and that, for example, PAD is more common in older patients and AAA is rarer 331 
in females. Nevertheless, we found cAIx to be higher in patients with PAD than in those with 332 
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AAA, especially in the well-matched male group (this relative elevation was corroborated 333 
using a regression analysis that controlled for further patient characteristics). Taken together 334 
the results were consistent across a range of analyses, indicating that the findings were robust. 335 
There were, however, some recognised weaknesses in the statistical analyses employed. Most 336 
importantly, the low number of observations and the significant overlap between patient 337 
groups led to multi-collinearity and therefore did not allow us to control for all patient 338 
characteristics simultaneously. Furthermore, due to the low number of observations and 339 
shared comorbidities, risk factors and medication, for both PAD and AAA, we cannot exclude 340 
the possibility of coincidental significance for certain patient characteristics. 341 
Our results, and those from other studies on cAIx in PAD and AAA patients, need to be 342 
considered in the context of vascular ageing and disease-related changes in vascular wall 343 
properties, and should be evaluated for clinical relevance. Age- and disease-related stiffening 344 
of the elastic arterial wall increases PWV and thereby impacts the antegrade and retrograde 345 
pulse waves similarly, resulting in central pressure augmentation. Based on the physiology of 346 
pulse wave propagation and reflexion, both an obstructive as well as an aneurysmatic vascular 347 
disease will have an impact on central aortic pressure hemodynamics. The central pressure 348 
augmentation has an unfavourable influence on systolic cardiac afterload and diastolic 349 
myocardial perfusion, both of which may be a factor for cardiovascular events such as stroke 350 
and myocardial infarction. Prognosis in both PAD and AAA patients is determined by 351 
cerebrovascular and cardiac events, as well as by disease-specific severe vascular 352 
complications such as gangrene and sepsis, or aneurysm rupture. Blood pressure management 353 
is an important preventative measure for all of these vascular complications. 354 
Central arterial blood pressure does not necessarily correspond to brachial arterial pressure 355 
due to the pressure pulse amplification phenomenon in the vascular bed. It has been shown 356 
that central pressures and arterial stiffness indices such as the central augmentation index 357 
(cAIx) might be of greater relevance than peripheral pressures in the pathogenesis of 358 
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cardiovascular events [42,43, 15, 44]. Hence, peripheral blood pressures might also not fully 359 
reflect the effects of medical treatment on blood pressure and cardiovascular risk markers, as 360 
shown in the sub-study of the ASCOT (CAFE) trial [45-46]. A better understanding of central 361 
hemodynamic markers and their predictive value for all-cause-mortality and cardiovascular 362 
risk, as well as their utility as follow-up markers for optimal blood pressure management, 363 
could lead to a new understanding of cardiovascular risk assessment. This applies in particular 364 
to patients with a known high-risk profile such as PAD and AAA. 365 
In conclusion, our study found that central aortic pressure augmentation was elevated in 366 
patients with PAD and AAA. cAIx was higher in PAD patients than in AAA patients. The 367 
elevation itself was not surprising given that atherosclerosis causes increased arterial stiffness. 368 
The relative degree of elevation in cAIx was significant but only descriptive. Therefore, in 369 
practice, when using cAIx for risk stratification, the sensitivity of cAIx with regard to 370 
vascular disease patterns has to be considered. 371 
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